Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edesa BiotechEDSA -3.08%26 Equity-to-Asset is 0.69 as of Jun. 2026, which is 21% below its 10-year median of 0.87. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Edesa Biotech ranks better than 51.2% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Edesa Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $8.81 Mil. Edesa Biotech's Total Assets for the quarter that ended in Jun. 2026 was $12.72 Mil.
The historical rank and industry rank for Edesa Biotech's Equity-to-Asset or its related term are showing as below:
EDSA'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52 Med: 0.87 Max: 0.97
Current: 0.69
During the past 13 years, the highest Equity to Asset Ratio of Edesa Biotech was 0.97. The lowest was 0.52. And the median was 0.87.
EDSA's Equity-to-Asset is ranked better than 51.2% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs EDSA: 0.69
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Edesa Biotech Equity-to-Asset Related Terms
Edesa Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Edesa Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDSA vs TCRX, DWTX, AURX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Edesa Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edesa Biotech Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Edesa Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Edesa Biotech's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech (EDSA) has a Equity-to-Asset of 0.69 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Edesa Biotech and its competitors. This is 21% below median its historical median of 0.87. Over the past decade, Edesa Biotech's Equity-to-Asset has ranged from 0.52 to 0.97. According to the industry distribution chart, Edesa Biotech ranks #691 out of 1416 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Edesa Biotech's Equity-to-Asset too high?
Edesa Biotech's current Equity-to-Asset of 0.69 is 21% below median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.68. Edesa Biotech's value of 0.69 is 1.5% above this industry median. Based on the distribution chart, Edesa Biotech ranks #691 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's Equity-to-Asset compare to TCRX and DWTX?
According to the Biotechnology industry distribution chart, Edesa Biotech ranks #691 out of 1416 companies for Equity-to-Asset. This puts Edesa Biotech in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Edesa Biotech's value of 0.69 is 1.5% above this benchmark. Historically, Edesa Biotech's own Equity-to-Asset has ranged from 0.52 to 0.97 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 0.68, Edesa Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edesa Biotech's current Equity-to-Asset of 0.69 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Edesa Biotech and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edesa Biotech's current Equity-to-Asset is 0.69, which is 21% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current Equity-to-Asset of 0.69. The current Equity-to-Asset is 0.69, which is 21% below median its 10-year median of 0.87 and 1.5% above the Biotechnology industry median of 0.68. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current Equity-to-Asset is 0.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score
Get the complete analysis for EDSA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDSA has been successfully added to your 
